Maxim Group Reinstates VNRX with a 'Buy' Rating and $4 Target

Maxim Group has reinstated its coverage of VNRX with a 'buy' rating and set a price target of $4, according to analyst Michael Okunewitch. This announcement was made on June 18, 2026, and comes as the stock trades around $1.43.

Other Institutional Activity in VNRX

Several institutional investors have recently adjusted their positions in VNRX. Lagoda Investment Management, L.P. significantly reduced its stake by 10,656,153 shares, ending with 807,450 shares valued at about $3.26 million. Meanwhile, Silverberg Bernstein Capital Management LLC slightly increased its holdings by 1,933 shares to 251,215 shares, worth approximately $50,745. Geode Capital Management, LLC also cut its position by 902,482 shares, leaving it with 61,504 shares valued at $248,510. Vanguard Capital Management LLC and Luminus Management LLC both established new positions, each holding 50,684 and 49,750 shares respectively.

VNRX Stock Snapshot

VNRX shares are currently trading near $1.43. The stock has seen significant volatility as institutional investors adjust their positions and analysts update their ratings.

Insider Buying and Selling at VolitionRx Limited

Recent insider activity at VNRX includes several sales by company executives. On March 17, 2026, Nicholas Plummer, General Counsel at Volition Diagnostics, sold 7,003 shares at an average price of $0.19. Similarly, Chief Scientific Officer Jacob Vincent Micallef sold 5,310 shares at the same price. Secretary Rodney Gerard Rootsaert and Chief Commercial Officer Gael Forterre also sold shares on the same day.

Analysts Set New Price Targets

On June 18, 2026, Maxim Group reinstated its coverage of VNRX with a 'buy' rating and a $4 price target. This follows other recent analyst activity, such as HC Wainwright & Co. maintaining a 'buy' rating with a $1 target on April 2, 2026, and D. Boral Capital maintaining a 'buy' with a $3 target on March 31, 2026. The consensus among analysts remains positive with a 'buy' recommendation.

Bottom Line

The recent analyst activity and institutional changes reflect ongoing interest and adjustments in VNRX's stock, with Maxim Group's reinstated 'buy' rating and $4 target suggesting potential upside. Investors often track these updates for insights, though it's important to remember that 13F filings and analyst ratings are backward-looking and may not reflect current conditions.